Second-line treatment of T790M-negative non-small cell lung cancer patients

by Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang
Published 2019-11-01

Treating patients with -positive non-small cell lung cancer: latest evidence and management strategy

by Bin-Chi Liao, Chia-Chi Lin, Jin-Yuan Shih, James Chih-Hsin Yang
Published 2015-09-01

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors

by Bin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, Chia-Chi Lin, Shu-Yung Lin, Yee-Fan Lee, Chao-Chi Ho, Jin-Yuan Shih, Yeun-Chung Chang, Chong-Jen Yu, James Chih-Hsin Yang, Pan-Chyr Yang
Published 2018-04-01

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

by Bin-Chi Liao, MD, Wei-Hsun Hsu, MD, Jih-Hsiang Lee, MD, Ching-Yao Yang, MD, PhD, Tzu-Hsiu Tsai, MD, PhD, Wei-Yu Liao, MD, PhD, Chao-Chi Ho, MD, PhD, Chia-Chi Lin, MD, PhD, Jin-Yuan Shih, MD, PhD, Chong-Jen Yu, MD, PhD, Ross A. Soo, M.B.B.S., James Chih-Hsin Yang, MD, PhD
Published 2021-01-01